The WHO recognizes 3 distinct sub-categories of AML based on somatic mutations: AML with NPM1 mutation, AML with bi-allelic mutations of CEBPA, and AML with mutated RUNX1 (provisional entity). Here, RUNX1 is linked to acute myeloid leukemia.